C
Cerevast Therapeutics
Medical technology company developing treatments for acute ischemic stroke and other vascular disorders
About Cerevast Therapeutics
Cerevast Therapeutics, Inc. operates as a late-stage medical technology company with a sharp focus on developing treatments for significant vascular disorders, primarily acute ischemic stroke. The company was established in September 2009, born from the acquisition of assets from ImaRx Therapeutics, a developer of microsphere contrast agents.
The firm is steered by President and CEO Bradford A. Zakes, who has held the position since its inception. His extensive 30-year background in the pharmaceutical, biotechnology, and med-tech sectors includes roles at ICOS Corporation and Glaxo, where he contributed to the clinical development of major pharmaceuticals. This experience in drug and device development provides a strong foundation for Cerevast's strategic direction. The company's formation involved Zakes, formerly the CEO of ImaRx Therapeutics, transitioning to lead Cerevast after it acquired ImaRx's assets.
Cerevast's core business revolves around a therapeutic approach called SonoLysis, which is the application of ultrasound energy to break down blood clots. The company is developing non-invasive medical devices that, when used in conjunction with standard drug therapies, aim to improve patient outcomes. Its client base consists of healthcare providers in emergency and clinical settings, specifically those treating stroke and other vascular conditions like Retinal Vein Occlusion (RVO). The business model centers on securing regulatory approval for its devices and then commercializing them for use in hospitals and clinics.
The company's flagship product is the Clotbust-ER™, a proprietary ultrasonic headframe. This operator-independent device is engineered for rapid deployment in an emergency room to administer therapeutic ultrasound energy to the brain of a patient suffering an ischemic stroke. It is designed to be used with standard thrombolytic drug therapy (tPA) to dissolve blood clots more effectively and restore blood flow faster than drug therapy alone. The device, which incorporates multiple transducers into an adjustable headframe, received CE Mark clearance in Europe in December 2011, a significant milestone allowing for commercialization in that market. Cerevast also has a program targeting RVO, which combines its ocular ultrasound device with microbubbles from a strategic partner to treat the root cause of the condition. The company's pipeline includes development-stage programs for post-stroke recovery using transcranial ultrasound neuromodulation and enhanced drug delivery.
Financially, Cerevast has successfully navigated multiple funding rounds to support its extensive clinical trials and product development. The company has raised a total of $46.9 million over nine rounds, including a notable $11.4 million Series C round in March 2015. Key institutional investors include Swiftsure and Haiyin Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Bothell, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
- Investment activity
- 1 company, latest Jul 2013
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Mar 2015 | $11M | $46M | Haiyin Capital | — |
| DEBT✓Debt | Mar 2014 | $1.8M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Cerevast Therapeutics is 3K monthly website visits, up 347.8% over the last three months. Cerevast Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cerevast Therapeutics in the Bothell ecosystem
The Cerevast Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
UT Horizon Fund
Haiyin Capital
Other known investors1 additional known investor
University of Texas Health Science Center at Houston
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cerevast Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cerevast Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









